Combining vaccines, optimised supportive care, and therapeutics for Ebola virus disease increases survival

Lancet Infect Dis. 2024 Jun;24(6):560-562. doi: 10.1016/S1473-3099(24)00066-5. Epub 2024 Feb 7.

Authors

William A Fischer 2nd¹, David A Wohl²

Affiliations

¹ Institute for Global Health and Infectious Disease, Division of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: wfischer@med.unc.edu.
² Division of Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

PMID: 38340738
DOI: 10.1016/S1473-3099(24)00066-5

No abstract available

Publication types

News

MeSH terms

Antiviral Agents / therapeutic use
Ebola Vaccines* / administration & dosage
Ebola Vaccines* / immunology
Ebolavirus / immunology
Hemorrhagic Fever, Ebola* / prevention & control
Humans

Substances

Ebola Vaccines
Antiviral Agents